Penn's Lung Cancer Research Program has been at the forefront in understanding lung cancer and developing new and improved types of treatment therapies.
For decades, Penn researchers and clinicians have been nationally recognized leaders in understanding the causes of lung cancer, mesothelioma and related disorders, and in finding more effective forms of treatment.
Penn hematologists and oncologists are national and international leaders in developing and testing new therapies for cancer treatment and they are engaged in a broad range of basic and clinical research, clinical care and teaching related to the diagnosis and treatment of lung cancer.
A dedicated clinical trials staff, specializing in the treatment of all stages of lung cancer, offers multiple clinical trials including studies of:
- Targeted molecular therapy
- Vaccine and immunologic therapy
Individualized treatment approaches that include the pathological analysis of tumor material in order to personalize medical treatments are also being investigated.
Medical oncologists involved in the management of lung cancer include:
- Charu Aggarwal, MD, MPH
- Evan W. Alley, MD, PhD
- Joshua Michael Bauml, MD
- Christine A. Ciunci, MD, MSCE
- Roger B. Cohen, MD
- Tracey L. Evans, MD
- John A. Kosteva, MD
- Corey J. Langer, MD